prostate cancer

Should all prostate cancers be treated?

Posted by  | treatment

“Prostate cancer mortality has been declining since prostate cancer screening started in 1995,” says William G. Nelson, M.D., Ph.D., director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. “There’s no question that it works. The problem is diagnosing these cancers in men who aren’t threatened by the disease and then pursuing treatment." "When(...)

How common is prostate cancer?

Posted by  | Research

Prostate cancer is extremely common in the U.S. “It’s the most common life-threatening cancer in men, responsible for 26,000 deaths per year,” says William G. Nelson, M.D., Ph.D., director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. But there are a lot of prostate cancers that are not life-threatening, he says. “In autopsies(...)

What is PSA?

Posted by  | Prevention/Screening

“PSA, or prostate specific antigen, is an enzyme that normally appears in the ejaculate or central reproduction but when there’s a cancer present, it leaks into the circulation system so you can detect it in the bloodstream, where it becomes a marker of prostate cancer and other prostate diseases,” explains William G. Nelson, M.D., Ph.D.,(...)

Is there any test for prostate cancer that doesn’t depend on a blood test for PSA?

Posted by  | Prevention/Screening

“There are an increasing collection of tests that sample other aspects of prostate cancer in urine, blood or tissue, including acquired gene defects in the disease and acquired changes that cancers display that normal cells don’t,” says William G. Nelson, M.D., Ph.D., director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. “I would(...)

What you need to know about prostate cancer screening guidelines

Posted by  | Prevention/Screening

Prostate-specific antigen (PSA)-based screening for prostate cancer has received mixed reviews from different organizations, says William G. Nelson, M.D., Ph.D., director of the Johns Hopkins Kimmel Cancer Center. Today, the United States Preventive Services Task Force has posted draft recommendations for prostate screening that encourage men ages 55 - 69 to make individual decisions about(...)

ASCO’s Best of 2014

Posted by  | Uncategorized

What better way to begin 2015 than with a nod to our scientists who, according to the American Society of Clinical Oncology (ASCO), have led some of the past year's major achievements in clinical cancer research and care. The research, in the immunotherapy and prostate cancer fields and led by Johns Hopkins Kimmel Cancer Center(...)

Hormone Therapy Combined with Chemotherapy Increases Survival for Prostate Cancer Patients

Posted by  | treatment

Early results from a study funded by the National Institutes of Health (NIH) have shown that men with hormone-sensitive metastatic prostate cancer who have received a combination of the chemotherapy drug docetaxel and hormone therapy lived longer than patients who received hormone therapy alone. The study enrolled 790 men with metastatic prostate cancer who received(...)

Cancer News Review

Posted by  | Research

Prostate cancer topics abound in the latest Cancer News Review podcast.  Dr. Bill Nelson, director of the Johns Hopkins Kimmel Cancer Center, discusses Hopkins-led research, published in the New England Journal of Medicine, looking at the genetic similarities of men with a family history of prostate cancer. By looking at their genes, investigators were able to find a genetic marker for(...)

Top Trends in Cancer Research 2011

Posted by  | Prevention/Screening, Research

It's been a game-changing year in cancer research.  Doctors and scientists don't typically like to use those words, but here's why I think this is a turning point.  Scientists are churning out the genetic code of cancer cells as quickly as the cost of sequencing technology plummets.   Teams of researchers are looking for ways to add the new armory of cancer cell-targeted(...)